Kite Pharma gets Yescarta approval in Japan for large B-cell lymphoma
Kite Pharma, a subsidiary of Gilead Sciences, and Daiichi Sankyo have received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for their ... Read More
Gilead’s Kite to acquire CAR T-therapies developer Tmunity Therapeutics
Kite, an arm of Gilead Sciences, has agreed to acquire Tmunity Therapeutics, a Philadelphia-based clinical-stage biotech company focused on next-generation CAR T-therapies and technologies, for ... Read More
Arcellx, and Kite to jointly advance CART-ddBMCA for multiple myeloma
Arcellx, a US-based clinical-stage biotechnology company, and Kite, a Gilead company, are partnering to co-develop and co-commercialize the former’s CART-ddBCMA, a late-stage product candidate. CART-ddBCMA, ... Read More
Eli Lilly’s Emgality gets FDA green light for migraine prevention
Eli Lilly and Company has secured approval from the US Food and Drug Administration (FDA) for its migraine drug Emgality (galcanezumab-gnlm) as a preventative therapy ... Read More